Announcement • 22h
Angelalign Technology Inc. Launches Iortho Release 6.2 With New CBCT Visualization, Trimline Flexibility, And Redesigned Prescription Form Angelalign Technology Inc. launched iOrtho Release 6.2 with new improvements in CBCT visualization, new trimline flexibility and a redesigned Rx form. The release puts real clinical advances directly in doctors' hands, from fuller CBCT visualization featuring new 3D diagnostic views, to multiple trimline options, to a redesigned Rx for Primary and Refinement cases, alongside a set of optimizations that sharpen the tools doctors rely on day to day. Release 6.2 reflects Angel Aligner's continued investment in giving orthodontists the tools to treat with confidence. New improvements in CBCT Visualization: IRS (Intelligent Root System) Gold provides detailed 3D visualizations of cortical and cancellous bone, maxillary sinus, and airway structures for more comprehensive case evaluation. Updated color mapping also makes it easier to distinguish tissue types at-a-glance, helping doctors evaluate anatomical structures more efficiently during case review. Variable Trimline in Rx: For the first time, three trimline options — Standard (scalloped), Full-Arch High, and High at Posterior Teeth Only — are built directly into the Rx form, giving doctors more control at the prescription stage, before setup even starts. There's flexibility after the fact too: doctors can downgrade their trimline selection directly in iOrtho at approval, and upgrade from Posterior Only to Full-Arch on their own. Redesigned Prescription Form for Primary and Refinement Cases: For both Primary and Refinement cases, the prescription form is being redesigned for all users to give doctors more clinical control right at the point of prescription. Building on existing Rx capabilities, the updated form expands what doctors can specify at the prescription stage, giving them more clinical control before setup even begins. Refreshed Treatment Plan Interface: The 3D user interface has been redesigned to make planning faster and more intuitive. The 3D modification tools (Tooth, Features, Arch, Occlusal Plane) now sit in the top-right of the 3D view, so doctors can access and switch between them more easily. This helps doctors evaluate treatment options more efficiently and with greater confidence. Additional Improvements From Doctor Feedback: Beyond the major features, Release 6.2 includes several smaller improvements that came directly from doctor feedback. Each update addresses a specific request raised by orthodontists using the platform. iOrtho Release 6.2 went live July 1. 6699
Live News • Jul 08
Angelalign Technology Rolls Out iOrtho Release 6.2 With Advanced Aligner Planning Features Angelalign Technology has launched iOrtho Release 6.2 for its Angel Aligner system, adding deeper CBCT visualization, more flexible trimline options and a redesigned prescription form, with the upgraded platform going live nationwide on 1 July.
The company says the update gives orthodontists more clinical control across mild through to complex clear aligner cases, with features shaped by direct feedback from doctors to refine diagnostics and treatment planning.
Angelalign Technology shares last traded at HK$74.80, with the stock up 22.8% year to date, while the latest product rollout adds context to recent market interest in the company.
The key takeaway for investors is that Angelalign Technology is putting clear development effort into its core treatment planning software, which may influence how frequently professionals choose the platform and how sticky those relationships become over time. Recent Insider Transactions • Jul 04
Insider recently sold HK$4.5m worth of stock On the 25th of June, Huamin Li sold around 68k shares on-market at roughly HK$66.62 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth HK$163m. Insiders have been net sellers, collectively disposing of HK$173m more than they bought in the last 12 months. 
